American biotechnology company at Union in New Jersey, based at the Institute for Life Science Entrepreneurship on the Kean University campus and registered for federal research awards since 2020. Works on new broad spectrum antifungal medicines against targets for which no approved drugs exist, using its own approach of redesigning existing drugs against indispensable targets, and has been funded through small business research awards from the national institute for allergy and infectious diseases.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen